Biopharming Regulations | GenomeWeb

Using genetic engineering in plants to create biopharmed drugs holds all sorts of promise for treating diseases, as the recent case of a drug which appears to have cured two Ebola patients has shown, but regulators may be holding this field back, argues Henry Miller in a Wall Street Journal op-ed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

Nothing to Fear

This Week in Science

For the Cavendish

Not 'Just a Theory'

Looking Ahead

This Week in PLOS

In Nature this week: epigenetic contributors to type 1 diabetes, assembly algorithm to detect structural variations, and more.

The Financial Times looks into how sequencing is moving into the clinic.

Mitochondrial replacement therapy may soon be occurring in the UK, according to the Guardian.

The US House of Representatives has passed the latest version of the 21st Century Cures Act.